CIK 0001619856 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Caribou Biosciences, Inc.
Sign in to watch- Ticker
- CRBU
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 453728228
- Phone
- 510-982-6030
- Business address
- 2929 7TH STREET, SUITE 105, BERKELEY, CA, 94710
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-21 | Braunstein Scott Director | Grant or award · Option to purchase Common Stock | +21,500 | 21,500 | ||
| 2023-02-21 | GUGGENHIME ANDREW Director | Grant or award · Option to purchase Common Stock | +21,500 | 21,500 | ||
| 2023-02-21 | MCCLUNG BARBARA G Chief Legal Officer | Grant or award · Option to purchase Common Stock | +131,000 | 131,000 | ||
| 2023-02-21 | Rizvi Syed Ali-aamir Chief Medical Officer | Grant or award · Option to purchase Common Stock | +131,000 | 131,000 | ||
| 2023-02-21 | Zheng Ran Director | Grant or award · Option to purchase Common Stock | +21,500 | 21,500 | ||
| 2023-02-21 | Whiting Nancy Director | Grant or award · Option to purchase Common Stock | +21,500 | 21,500 | ||
| 2023-02-21 | O'Byrne Jason Chief Financial Officer | Grant or award · Option to purchase Common Stock | +131,000 | 131,000 | ||
| 2023-02-21 | JOHNSON DAVID LEE Director | Grant or award · Option to purchase Common Stock | +21,500 | 21,500 | ||
| 2023-01-19 | Rizvi Syed Ali-aamir Chief Medical Officer | Sale | −5,627 | $6.31 | $36K | 59,373 |
| 2022-12-02 | Kanner Steven Chief Scientific Officer | Option exercise | +21,401 | $2.69 | $58K | 323,460 |
| 2022-12-02 | Kanner Steven Chief Scientific Officer | Option exercise · Option to purchase Common Stock | −21,401 | $2.69 | $58K | 52,200 |
| 2022-10-06 | Fischesser Ryan VP of Finance and Controller | Sale | −10,000 | $10.80 | $108K | 110,366 |
| 2022-10-06 | Fischesser Ryan VP of Finance and Controller | Option exercise | +2,839 | $2.69 | $8K | 113,205 |
| 2022-10-06 | Fischesser Ryan VP of Finance and Controller | Option exercise | +2,839 | $4.11 | $12K | 116,044 |
| 2022-10-06 | Fischesser Ryan VP of Finance and Controller | Option exercise · Option to purchase Common Stock | −2,839 | 1,704 | ||
| 2022-10-06 | Fischesser Ryan VP of Finance and Controller | Option exercise · Option to purchase Common Stock | −2,839 | 15,337 | ||
| 2022-09-15 | MCCLUNG BARBARA G Chief Legal Officer | Option exercise | +77 | $2.69 | $207 | 349,048 |
| 2022-09-15 | MCCLUNG BARBARA G Chief Legal Officer | Option exercise | +27,518 | $2.69 | $74K | 376,566 |
| 2022-09-15 | MCCLUNG BARBARA G Chief Legal Officer | Option exercise · Option to purchase Common Stock | −77 | 0 | ||
| 2022-09-15 | MCCLUNG BARBARA G Chief Legal Officer | Option exercise · Option to purchase Common Stock | −27,518 | 47,318 |
Page 5 of 9 · 177 trades